Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...

Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the age ...

Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...

Please provide your email address to receive an email when new articles are posted on . Fears associated with needles may cause patients and caregivers to delay their use of epinephrine autoinjectors.

First self-administered, needle-free injection system approved by Health Canada gives access to safe, painless, cost-effective, and more sustainable drug delivery for chronic illnesses Toronto, ...

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...